Aptinyx Inc. (APTX) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Aptinyx Inc. (APTX) Healthcare & Pipeline Overview

Aptinyx Inc. is a clinical-stage biopharmaceutical firm specializing in novel small molecule therapeutics for brain and nervous system disorders. Their focus on N-methyl-D-aspartate receptor (NMDAr) modulators distinguishes them within the biotechnology sector, addressing unmet needs in conditions like fibromyalgia, PTSD, and Parkinson’s disease.

What Is the Investment Thesis for APTX?

Aptinyx presents a high-risk, high-reward investment profile typical of clinical-stage biopharmaceutical companies. The core value driver lies in the successful progression of its NMDAr modulator pipeline through clinical trials, particularly NYX-2925, NYX-783, and NYX-458. Positive Phase II results could trigger significant stock appreciation. Key catalysts include data readouts from ongoing Phase II trials for fibromyalgia and PTSD expected in late 2026. However, the company faces substantial risks related to clinical trial failures, regulatory hurdles, and the need for additional funding. The company's beta of 1.22 suggests higher volatility compared to the broader market.

Based on FMP financials and quantitative analysis

APTX Key Highlights

• NYX-2925 is in Phase II clinical development for painful diabetic peripheral neuropathy.
• NYX-2925 is also in Phase II/b clinical trial for treating fibromyalgia.
• NYX-783, an NMDAr modulator, is in Phase II/b clinical trial to treat post-traumatic stress disorder.
• NYX-458, an NMDAr modulator, is in Phase II clinical study for the treatment of Parkinson's disease cognitive impairment.
• Aptinyx has a research collaboration agreement with Allergan plc.

Who Are APTX's Competitors?

APTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are APTX's Key Strengths?

• Novel NMDAr modulator technology platform.
• Pipeline of clinical-stage assets.
• Research collaboration with Allergan (AbbVie).
• Experienced management team.

What Are APTX's Weaknesses?

• Clinical-stage company with no approved products.
• High cash burn rate.
• Dependence on successful clinical trial outcomes.
• Small number of employees.

What Could Drive APTX Stock Higher?

• Data readout from Phase II/b clinical trial of NYX-2925 in fibromyalgia (late 2026).
• Data readout from Phase II/b clinical trial of NYX-783 in post-traumatic stress disorder (late 2026).
• Progression of NYX-458 through Phase II clinical study for Parkinson's disease cognitive impairment.
• Potential expansion of research collaboration with AbbVie.

What Are the Key Risks for APTX?

• Financial-distress signal — its Altman Z-Score of -14.46 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-97.5%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Failure of NYX-2925 in Phase II clinical trials for painful diabetic peripheral neuropathy or fibromyalgia.
• Failure of NYX-783 in Phase II/b clinical trial for post-traumatic stress disorder.
• Regulatory delays or rejection of drug candidates by the FDA.
• Need for additional funding to support clinical development programs.
• Competition from other pharmaceutical companies developing treatments for brain and nervous system disorders.

What Are the Growth Opportunities for APTX?

• Expansion of NYX-2925 into Additional Pain Indications: Beyond diabetic peripheral neuropathy and fibromyalgia, NYX-2925 could be explored for other chronic pain conditions. The global pain management market is projected to reach $91.4 billion by 2028, offering a substantial opportunity if NYX-2925 demonstrates broad efficacy and safety. This expansion would require further clinical trials and regulatory approvals, potentially extending the timeline to commercialization by 3-5 years.
• Advancement of NYX-783 for Broader Psychiatric Applications: The success of NYX-783 in treating PTSD could pave the way for its investigation in other psychiatric disorders, such as anxiety and depression. The market for antidepressants and anti-anxiety medications is significant, estimated at $16 billion globally. Expanding the label for NYX-783 would necessitate additional clinical trials and regulatory submissions, potentially adding 4-6 years to the development timeline.
• Out-Licensing or Partnership Agreements for Pipeline Assets: Aptinyx could pursue out-licensing or partnership agreements with larger pharmaceutical companies to accelerate the development and commercialization of its pipeline assets. This strategy would provide upfront funding, reduce development costs, and leverage the expertise of a larger organization. The timeline for such agreements is variable, but could potentially occur within the next 1-2 years.
• Development of Novel NMDAr Modulators for Cognitive Impairment: Aptinyx can leverage its expertise in NMDAr modulation to develop new therapies for cognitive impairment associated with various neurological disorders, including Alzheimer's disease and mild cognitive impairment (MCI). The market for Alzheimer's disease treatments is projected to reach $13.7 billion by 2030. This would involve preclinical research, clinical trials, and regulatory approvals, potentially taking 5-7 years.
• Expansion of Research Collaboration with Allergan (AbbVie): Aptinyx could expand its research collaboration with Allergan (now AbbVie) to explore new therapeutic targets and develop novel NMDAr modulators. This collaboration would provide access to additional funding, expertise, and resources. The timeline for expanding the collaboration is uncertain, but could potentially occur within the next 1-3 years.

What Opportunities Does APTX Have?

• Expansion into new therapeutic areas.
• Out-licensing or partnership agreements.
• Positive clinical trial results.
• Increasing prevalence of brain and nervous system disorders.

What Threats Does APTX Face?

• Clinical trial failures.
• Regulatory hurdles.
• Competition from other pharmaceutical companies.
• Patent challenges.

What Are APTX's Competitive Advantages?

• Proprietary NMDAr modulator technology platform.
• Pipeline of clinical-stage assets targeting unmet medical needs.
• Intellectual property protection for its drug candidates.
• Research collaboration with Allergan (AbbVie).

What Does APTX Do?

Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois. The company is dedicated to the discovery, development, and commercialization of innovative treatments for challenging brain and nervous system disorders. Aptinyx focuses on developing novel, proprietary, and synthetic small molecules designed to modulate N-methyl-D-aspartate receptors (NMDAr). Their pipeline includes NYX-2925, currently in Phase II clinical development for painful diabetic peripheral neuropathy and Phase II/b for fibromyalgia. Additionally, NYX-783, another NMDAr modulator, is in Phase II/b clinical trials for post-traumatic stress disorder (PTSD). NYX-458, also an NMDAr modulator, is undergoing Phase II clinical study for Parkinson's disease cognitive impairment. Aptinyx operates through research and development, seeking to create value through clinical trial advancement and potential commercialization. The company also has a research collaboration agreement with Allergan plc, highlighting its collaborative approach to drug development.

What Products and Services Does APTX Offer?

• Develop novel small molecule therapeutics for brain and nervous system disorders.
• Focus on modulating N-methyl-D-aspartate receptors (NMDAr).
• Conduct Phase II clinical trials for NYX-2925 in painful diabetic peripheral neuropathy.
• Conduct Phase II/b clinical trials for NYX-2925 in fibromyalgia.
• Conduct Phase II/b clinical trials for NYX-783 in post-traumatic stress disorder (PTSD).
• Conduct Phase II clinical study for NYX-458 in Parkinson's disease cognitive impairment.

How Does APTX Make Money?

• Discover and develop novel small molecule therapeutics.
• Conduct preclinical and clinical trials to evaluate safety and efficacy.
• Seek regulatory approval from the FDA and other agencies.
• Potentially commercialize approved products directly or through partnerships.
• Generate revenue through product sales, licensing agreements, and research collaborations.

What Industry Does APTX Operate In?

Aptinyx operates within the competitive biotechnology industry, which is characterized by high R&D spending, lengthy development timelines, and significant regulatory oversight. The market for treatments targeting brain and nervous system disorders is substantial, driven by an aging population and increasing prevalence of conditions like Alzheimer's, Parkinson's, and PTSD. Aptinyx's focus on NMDAr modulation places it among companies exploring novel mechanisms of action to address unmet needs in these therapeutic areas. Success depends on clinical trial outcomes and regulatory approvals.

Who Are APTX's Key Customers?

• Patients suffering from brain and nervous system disorders.
• Physicians who prescribe medications for these conditions.
• Healthcare providers and hospitals.
• Pharmaceutical companies through potential licensing agreements.

Net buyingInsider Activity

The most recent 12 insider filings for Aptinyx Inc. break down as 0 sales and 12 purchases. On net that is roughly 1.9M shares acquired (about $60K) — insiders putting money in tends to read as conviction.

APTX Valuation & Market Position

Relative to its peer group, APTX's quantitative score of 46/100 is below the peer average of 78/100.

ROE -97%Key Financial Metrics

Return on equity for Aptinyx Inc. stands at -97.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -97.2%, showing how much profit it generates from its asset base. A current ratio of 10.18 indicates the company holds enough short-term assets to cover its near-term obligations.

F-Score 1/9Financial Health

Aptinyx Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -14.46 places it in the distress zone, a signal of elevated financial risk.

Company Profile

Aptinyx Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Evanston, US. The company is led by CEO Craig R. Jalbert CIRA. APTX has traded publicly since 2018.

APTX Financials

APTX Latest News

APTX Analyst Consensus

APTX MoonshotScore

Aptinyx Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources